Abstract
ALX-0081 is a novel nano-antibody inhibiting von Willebrand factor (vWF). We evaluated whether direct inhibition of vWF by ALX-0081 improves endothelial function. Stable patients (pts, n = 55) with single vessel disease undergoing percutaneous coronary intervention (PCI) were randomized to ALX-0081 (n = 38) or placebo (n = 17). vWF inhibition was assessed by vWF antigen level (vWF:Ag) and activity by ristocetin test (vWF:RiCo). Endothelial function was assessed before (BL), 6 h and 24 h after PCI by: (a) endothelial peripheral arterial tonometry (Endoscore); (b) endothelial microparticles (EMPs) by flow cytometry. vWF:Ag and vWF:RiCo decreased within 1 h from ALX-0081. In the placebo group, no significant Endoscore changes occurred from BL to 24 h. In ALX-0081 group, Endoscore increased from BL to 24 h (p = 0.014). A decrease in EMPs was observed after ALX-0081 (p < 0.01), while no changes occurred in placebo pts. An inhibition of vWF with ALX-0081 significantly improves peripheral endothelial function.
Similar content being viewed by others
References
Reriani, M. K., Lerman, L. O., & Lerman, A. (2010). Endothelial function as a functional expression of cardiovascular risk factors. Biomarkers in Medicine, 4(3), 351–360.
Lembo, G., Morisco, C., Lanni, F., Barbato, E., Vecchione, C., Fratta, L., & Trimarco, B. (1998). Systemic hypertension and coronary artery disease: the link. The American Journal of Cardiology, 82, 2H–7H.
Barbato, E., Bartunek, J., Wyffels, E., Wijns, W., Heyndrickx, G. R., & De Bruyne, B. (2003). Effects of intravenous dobutamine on coronary vasomotion in humans. Journal of the American College of Cardiology, 42, 1596–1601.
Barbato, E., Piscione, F., Bartunek, J., Galasso, G., Cirillo, P. L., De Luca, G., Iaccarino, G., De Bruyne, B., Chiariello, M., & Wijns, W. (2005). Role of beta2 adrenergic receptors in human atherosclerotic coronary arteries. Circulation, 111(3), 288–294.
Bonetti, P. O., Lerman, L. O., & Lerman, A. (2003). Endothelial dysfunction: a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 23(2), 168–175.
Brevetti, G., Piscione, F., Cirillo, P., Galasso, G., Schiano, V., Barbato, E., Scopacasa, F., & Chiariello, M. (2008). In concomitant coronary and peripheral arterial disease, inflammation of the affected limbs predicts coronary artery endothelial dysfunction. Atherosclerosis, 201(2), 440–446.
Treasure, C. B., Klein, J. L., Weintraub, W. S., Talley, J. D., Stillabower, M. E., Kosinski, A. S., Zhang, J., Boccuzzi, S. J., Cedarholm, J. C., & Alexander, R. W. (1995). Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. The New England Journal of Medicine, 332(8), 481–487.
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Jr., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., Nordestgaard, B. G., Shepherd, J., Willerson, J. T., & Glynn, R. J. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine, 359(21), 2195–2207.
Hambrecht, R., Wolf, A., Gielen, S., Linke, A., Hofer, J., Erbs, S., Schoene, N., & Schuler, G. (2000). Effect of exercise on coronary endothelial function in patients with coronary artery disease. The New England Journal of Medicine, 342(7), 454–460.
Hamilos, M., Sarma, J., Ostojic, M., Cuisset, T., Sarno, G., Melikian, N., Ntalianis, A., Muller, O., Barbato, E., Beleslin, B., Sagic, D., De Bruyne, B., Bartunek, J., & Wijns, W. (2008). Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. Circulation Cardiovascular Interventions, 1(3), 193–200.
Vischer, U. M. (2006). von Willebrand factor, endothelial dysfunction, and cardiovascular disease. Journal of Thrombosis and Haemostasis, 4(6), 1186–1193.
Muller, O., Hamilos, M., Bartunek, J., Ulrichts, H., Mangiacapra, F., Holz, JB., et al. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. American Journal of Cardiology, 105(3), 333–338
Bickel, C., Rupprecht, H. J., Blankenberg, S., Espinola-Klein, C., Rippin, G., Hafner, G., Lotz, J., Prellwitz, W., & Meyer, J. (2002). Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. International Journal of Cardiology, 82(1), 25–31.
Companion paper from Bartunek, J., & Holtz J. (2013). Novel antiplatelet agents: ALX-0081, a nanobody directed toward von Willebrand factor. Journal Cardiovascular Translational Research
Cuisset, T., Hamilos, M., Melikian, N., Wyffels, E., Sarma, J., Sarno, G., Barbato, E., Bartunek, J., Wijns, W., & De Bruyne, B. (2008). Direct stenting for stable angina pectoris is associated with reduced periprocedural microcirculatory injury compared with stenting after pre-dilation. Journal of the American College of Cardiology, 51(11), 1060–1065.
Hamburg, N. M., Keyes, M. J., Larson, M. G., Vasan, R. S., Schnabel, R., Pryde, M. M., Mitchell, G. F., Sheffy, J., Vita, J. A., & Benjamin, E. J. (2008). Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham heart study. Circulation, 117(19), 2467–2474.
Cuisset, T., Hamilos, M., Sarma, J., Sarno, G., Wyffels, E., Vanderheyden, M., Barbato, E., Bartunek, J., De Bruyne, B., & Wijns, W. (2008). Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. The American Journal of Cardiology, 101(12), 1700–1703.
Mangiacapra, F., De Bruyne, B., Muller, O., Trana, C., Ntalianis, A., Bartunek, J., Heyndrickx, G., Di Sciascio, G., Wijns, W., & Barbato, E. (2010). High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. Journal American College of Cardiology Cardiovasc Intervention, 3(1), 35–40.
Hamilos, M., Muller, O., Ntalianis, A., Trana, C., Bartunek, J., Sarno, G., Mangiacapra, F., Dierickx, K., Meeus, P., Cuisset, T., De Bruyne, B., Wijns, W., & Barbato, E. (2011). Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. Journal of Thrombosis and Thrombolysis, 32(1), 64–71.
Ulrichts, H., Silence, K., Schoolmeester, A., de Jaegere, P., Rossenu, S., Roodt, J., Priem, S., Lauwereys, M., Casteels, P., Van Bockstaele, F., Verschueren, K., Stanssens, P., Baumeister, J., & Holz, J. B. (2011). Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood, 118(3), 757–765.
Deanfield, J. E., Halcox, J. P., & Rabelink, T. J. (2007). Endothelial function and dysfunction: testing and clinical relevance. Circulation, 115(10), 1285–1295.
Hansson, G. K. (2005). Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine, 352(16), 1685–1695.
Jilma, B., Pernerstorfer, T., Dirnberger, E., Stohlawetz, P., Schmetterer, L., Singer, E. A., Grasseli, U., Eichler, H. G., & Kapiotis, S. (1998). Effects of histamine and nitric oxide synthase inhibition on plasma levels of von Willebrand factor antigen. The Journal of Laboratory and Clinical Medicine, 131(2), 151–156.
Pernerstorfer, T., Stohlawetz, P., Kapiotis, S., Eichler, H. G., & Jilma, B. (2000). Partial inhibition of nitric oxide synthase primes the stimulated pathway of vWF-secretion in man. Atherosclerosis, 148(1), 43–47.
Golino, P., Buja, L. M., Ashton, J. H., Kulkarni, P., Taylor, A., & Willerson, J. T. (1988). Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries. Circulation, 78(3), 701–711.
Yao, S. K., Ober, J. C., McNatt, J., Benedict, C. R., Rosolowsky, M., Anderson, H. V., Cui, K., Maffrand, J. P., Campbell, W. B., & Buja, L. M. (1992). ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circulation Research, 70(1), 39–48.
Bush, L. R., Campbell, W. B., Buja, L. M., Tilton, G. D., & Willerson, J. T. (1984). Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation, 69(6), 1161–1170.
McGhie, A. I., McNatt, J., Ezov, N., Cui, K., Mower, L. K., Hagay, Y., Buja, L. M., Garfinkel, L. I., Gorecki, M., & Willerson, J. T. (1994). Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain. Circulation, 90(6), 2976–2981.
Bonetti, P. O., Barsness, G. W., Keelan, P. C., Schnell, T. I., Pumper, G. M., Kuvin, J. T., Schnall, R. P., Holmes, D. R., Higano, S. T., & Lerman, A. (2003). Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. Journal of the American College of Cardiology, 41(10), 1761–1768.
Kuvin, J. T., Patel, A. R., Sliney, K. A., Pandian, N. G., Sheffy, J., Schnall, R. P., Karas, R. H., & Udelson, J. E. (2003). Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. American Heart Journal, 146(1), 168–174.
Krantz, D. S., Santiago, H. T., Kop, W. J., Bairey Merz, C. N., Rozanski, A., & Gottdiener, J. S. (1999). Prognostic value of mental stress testing in coronary artery disease. American Journal of Cardiology, 84(11), 1292–1297.
Lavie, P., Shlitner, A., Sheffy, J., & Schnall, R. P. (2000). Peripheral arterial tonometry: a novel and sensitive non-invasive monitor of brief arousals during sleep. The Israel Medical Association Journal, 2(3), 246–247.
Bonetti, P. O., Pumper, G. M., Higano, S. T., Holmes, D. R., Jr., Kuvin, J. T., & Lerman, A. (2004). Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. Journal of the American College of Cardiology, 44(11), 2137–2141.
Rubinshtein, R., Kuvin, J. T., Soffler, M., Lennon, R. J., Lavi, S., Nelson, R. E., Pumper, G. M., Lerman, L. O., & Lerman, A. (2010). Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. European Heart Journal, 31(9), 1142–1148.
Woywodt, A., Bahlmann, F. H., De Groot, K., Haller, H., & Haubitz, M. (2002). Circulating endothelial cells: life, death, detachment and repair of the endothelial cell layer. Nephrology, Dialysis, Transplantation, 17(10), 1728–1730.
Mallat, Z., Benamer, H., Hugel, B., Benessiano, J., Steg, P. G., Freyssinet, J. M., & Tedgui, A. (2000). Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation, 101(8), 841–843.
Hamilos, H., Sarma, J., Ostojic, M., Cuisset, T., Sarno, G., Melikian, N., Ntalianis, A., Muller, O., Barbato, E., Belesin, B., Sagic, D., De Bruyne, B., Bartunek, J., & Wijns, W. (2008). Interference of drug-eluting stents with endothelium-dependant coronary vasomotion. Circulation: Cardiovascular Intervention, 1, 193–200.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Muller, O., Bartunek, J., Hamilos, M. et al. von Willebrand Factor Inhibition Improves Endothelial Function in Patients with Stable Angina. J. of Cardiovasc. Trans. Res. 6, 364–370 (2013). https://doi.org/10.1007/s12265-012-9422-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12265-012-9422-3